GLP-1 & Incretin Science

What Is CagriSema? Cagrilintide Plus Semaglutide

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

CagriSema is a once-weekly fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist, both at 2.4 mg. In the REDEFINE 1 trial it produced 22.7% mean weight reduction at 68 weeks among participants who adhered to treatment, and 20.4% across all participants regardless of adherence.

Key facts

Components
Cagrilintide 2.4 mg + semaglutide 2.4 mg
Developer
Novo Nordisk
Administration
Once weekly, subcutaneous
Trial
REDEFINE 1, 68 weeks
Efficacy estimand
22.7% mean reduction
Treatment-policy estimand
20.4% mean reduction
Placebo
2.3% and 3.0% respectively
Head-to-head
REDEFINE 4: non-inferiority not met

What amylin adds

Amylin is a 37-residue hormone co-secreted with insulin by pancreatic beta cells. It slows gastric emptying and signals satiety through pathways distinct from GLP-1, principally in the area postrema. Cagrilintide is a long-acting amylin analogue engineered for weekly dosing. Combining it with semaglutide targets two separate satiety mechanisms rather than pushing harder on one, which is the design rationale behind the whole amylin-combination strategy.

What REDEFINE 1 reported

REDEFINE 1 ran 68 weeks and compared CagriSema against cagrilintide alone, semaglutide alone and placebo, all once weekly. Mean weight reduction was 22.7% among participants who adhered to treatment against 2.3% on placebo, and 20.4% across all randomised participants against 3.0%. Both figures are correct; they answer different questions, and which one gets quoted changes the apparent result by more than two percentage points.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The threshold results

Proportions reaching each level of reduction at 68 weeks were reported as follows. A supportive analysis also found that 50.7% of participants with obesity reached a BMI below 30 by end of treatment, from a mean baseline BMI of 38, against 10.2% on placebo.

  • ≥5% reduction: 97.6% of participants
  • ≥20% reduction: 60.2%
  • ≥25% reduction: 40.4%
  • ≥30% reduction: 23.1%
  • Reached BMI below 30: 50.7% (vs 10.2% placebo)

How it compares with retatrutide

Retatrutide's TRIUMPH-1 reported 28.3% at 80 weeks against CagriSema's 22.7% at 68 weeks. The comparison is indirect and the durations differ, so the gap should not be read as exact. What is clear is that both approaches (adding amylin, and adding GIP plus glucagon) produce substantially more reduction than GLP-1 alone.

Status

CagriSema results were presented at the American Diabetes Association's 85th Scientific Sessions and published simultaneously in the New England Journal of Medicine. It is under regulatory review rather than authorised, and is not available in the UK.

The head-to-head against tirzepatide

REDEFINE 4, registered as NCT06131437, randomised 809 adults to CagriSema or tirzepatide 15 mg over 84 weeks. Its primary objective was to confirm non-inferiority of CagriSema, and that objective was not met: 23.0% against 25.5% on the efficacy estimand, and 20.2% against 23.6% on the treatment-policy estimand. Failing to demonstrate non-inferiority is not the same as demonstrating inferiority, and 23.0% remains a large reduction.

Frequently asked questions

Why are two different weight-loss figures quoted for CagriSema?

They are different estimands. 22.7% describes participants who adhered to treatment; 20.4% describes everyone randomised regardless of adherence. Both are legitimate and they answer different questions.

Is cagrilintide a GLP-1 drug?

No. It is an amylin analogue. Amylin is a separate hormone with its own receptor and its own satiety pathway, which is why combining the two adds effect.

Is CagriSema available in the UK?

No. It is not authorised by the MHRA.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.